Learn About IPEX Syndrome

What is the definition of IPEX Syndrome?

Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome primarily affects males and is caused by problems with the immune system. The immune system normally protects the body from foreign invaders, such as bacteria and viruses, by recognizing and attacking these invaders and clearing them from the body. However, the immune system can malfunction and attack the body's own tissues and organs instead, which is known as autoimmunity. IPEX syndrome is characterized by the development of multiple autoimmune disorders in affected individuals. Although IPEX syndrome can affect many different areas of the body, autoimmune disorders involving the intestines, skin, and hormone-producing (endocrine) glands occur most often. IPEX syndrome can be life-threatening in early childhood.

What are the causes of IPEX Syndrome?

Mutations in the FOXP3 gene cause IPEX syndrome. The protein produced from this gene is a transcription factor, which means that it attaches (binds) to specific regions of DNA and helps control the activity of particular genes. This protein is essential for the production and normal function of certain immune cells called regulatory T cells. Regulatory T cells play an important role in controlling immune responses and preventing autoimmune disorders. Mutations in the FOXP3 gene impair the normal function of regulatory T cells, making it difficult for the body to turn off immune responses when they are not needed. Normal body tissues and organs are attacked, causing the multiple autoimmune disorders that develop in people with IPEX syndrome.

How prevalent is IPEX Syndrome?

IPEX syndrome is a rare disorder that affects an estimated 1 in 1.6 million people.

Is IPEX Syndrome an inherited disorder?

IPEX syndrome is inherited in an X-linked recessive pattern. The FOXP3 gene is located on the X chromosome, which is one of the two sex chromosomes. In males (who have only one X chromosome), one altered copy of the gene in each cell is sufficient to cause the condition. In females (who have two X chromosomes), a mutation must be present in both copies of the gene to cause the disorder. Males are affected by X-linked recessive disorders much more frequently than females. A characteristic of X-linked inheritance is that fathers cannot pass X-linked traits to their sons.

Who are the top IPEX Syndrome Local Doctors?
Elite in IPEX Syndrome
Elite in IPEX Syndrome
Milan, IT 

Laura Passerini practices in Milan, Italy. Ms. Passerini is rated as an Elite expert by MediFind in the treatment of IPEX Syndrome. Her top areas of expertise are IPEX Syndrome, Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome), Diarrhea, Type 1 Diabetes (T1D), and Bone Marrow Transplant.

Distinguished in IPEX Syndrome
Distinguished in IPEX Syndrome
Tokyo, JP 

Hirokazu Kanegane practices in Tokyo, Japan. Kanegane is rated as a Distinguished expert by MediFind in the treatment of IPEX Syndrome. Their top areas of expertise are X-Linked Lymphoproliferative Disease, Primary Immunodeficiency (PID), IPEX Syndrome, ZAP70-Related Severe Combined Immunodeficiency, and Bone Marrow Transplant.

 
 
 
 
Learn about our expert tiers
Learn More
Distinguished in IPEX Syndrome
Distinguished in IPEX Syndrome
Sapporo, JP 

Ichiro Kobayashi practices in Sapporo, Japan. Mr. Kobayashi is rated as a Distinguished expert by MediFind in the treatment of IPEX Syndrome. His top areas of expertise are IPEX Syndrome, Juvenile Dermatomyositis, Kikuchi Disease, and Dermatomyositis.

What are the latest IPEX Syndrome Clinical Trials?
A Phase II Study of Reduced Intensity Conditioning in Pediatric Patients and Young Adults ≤55 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood, Bone Marrow, or Peripheral Blood Stem Cell Transplantation

Summary: The objective of this study is to evaluate the efficacy of using a reduced-intensity condition (RIC) regimen with umbilical cord blood transplant (UCBT), double cord UCBT, matched unrelated donor (MUD) bone marrow transplant (BMT) or peripheral blood stem cell transplant (PBSCT) in patients with non-malignant disorders that are amenable to treatment with hematopoietic stem cell transplant (HSCT). ...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Prospective Outcomes Study of Pediatric and Adult Patients with Non-Malignant Disorders Undergoing Umbilical Cord Blood, Bone Marrow, or Peripheral Blood Stem Cell Transplantation with a Reduced-Intensity Conditioning Regimen (PRO-RIC)

Summary: This is a data collection study that will examine the general diagnostic and treatment data associated with the reduced-intensity chemotherapy-based regimen paired with simple alemtuzumab dosing strata designed to prevented graft failure and to aid in immune reconstitution following hematopoietic stem cell transplantation.

Who are the sources who wrote this article ?

Published Date: May 01, 2017
Published By: National Institutes of Health